Hepatology International

10/07/2025

Discover how systemic inflammatory response markers enhance prognostic accuracy in hepatocellular carcinoma (HCC). This study presents important findings that improve current risk stratification models and support more precise clinical decision-making.

📖 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10806-6

07/07/2025

Explore the latest evidence on achieving a functional cure for hepatitis B virus with emerging antiviral therapies in this comprehensive systematic review and meta-analysis. This article evaluates the efficacy and potential of novel treatment strategies that could reshape HBV management.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10823-5

02/07/2025

🌍 Join us for APASL 2025 Moscow – STC on Alcoholic Liver Disease, an international platform dedicated to the latest advances in research, prevention, and treatment of alcoholic liver disease.

📅 Coming this September 2025

We are excited to welcome leading experts, clinicians, and researchers to share knowledge, exchange insights, and shape the future of liver health. Don’t miss this opportunity to learn and connect!

🔗 For more details and registration, visit: https://apasl-moscow.ru/en/

APASL Single topic conference «Alcoholic liver disease»

01/07/2025

A new article in Hepatology International examines emerging therapies for HBsAg seroclearance, with a focus on innovative novel combination strategies that hold promise for functional cure. This comprehensive review offers critical insights for clinicians and researchers alike.

🔗 Read the full article here: https://link.springer.com/article/10.1007/s12072-025-10828-0

10/06/2025

📢 Join us at APASL STC Oncology Taiwan 2025!

📅 5–7 September 2025
📍 Taipei Marriott Hotel, Taiwan

This year's theme, "Multifaceted Approach and Treatment for Liver Cancer," will bring together leading experts to share the latest advancements in liver oncology.

Don't miss this vital gathering of the hepatology and oncology communities.
🔗 Register and learn more: www.apasl-oncology2025.org

On behalf of the Organizing Committee, it is my great pleasure to extend a warm welcome to you all to the APASL Single Topic Conference (STC) on Oncology, to be held in the vibrant city of Taipei, Taiwan, from September 7-9, 2025. We are honored to invite you to join us in exploring the latest advan...

09/06/2025

📄 Explore the results of a Phase 1 dose escalation trial on the sequential combination of ropeginterferon alfa-2b and anti-PD-1 therapy as adjuvant treatment in HBV-related hepatocellular carcinoma (HCC). This study offers valuable insights into the safety and potential efficacy of novel immunomodulatory strategies in post-operative settings.

Read the full article here: https://link.springer.com/article/10.1007/s12072-025-10824-4

22/05/2025

📢 Save the Date!
Join global hepatology experts at APASL STC Tokyo 2025, taking place from 2–3 October 2025 at the Toshi Center Hotel, Tokyo, Japan.

Chaired by Dr. Kenichi Ikejima, this focused scientific meeting will explore cutting-edge developments in liver disease research and clinical care.

🔗 Learn more and register now: www.apasl-stc2025tokyo.org

19/05/2025

"The Promise of Incretin-Based Pharmacotherapies for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)" explores emerging therapeutic strategies targeting the incretin axis. This article highlights the evolving role of GLP-1 receptor agonists and related agents in addressing the complex metabolic and hepatic landscape of MAFLD.

A must-read for clinicians and researchers advancing the frontiers of hepatometabolic care.

28/04/2025

Publishing your article open access (OA) with Springer can increase downloads, citations, and global accessibility. 🌍 Many institutions now cover OA publishing costs through agreements with Springer Nature—making it easier than ever to share your work with the world.

Learn more about OA agreements here: https://www.springernature.com/gp/open-science/oa-agreements

16/04/2025

New evidence highlights the critical role of inflammation in liver cancer prognosis.

A recent study in Hepatology International demonstrates how systemic inflammatory response markers significantly improve discrimination in prognostic models for hepatocellular carcinoma (HCC)—enhancing risk stratification and guiding clinical decision-making.

🔗 Read the full article here: https://link.springer.com/article/10.1007/s12072-025-10806-6

14/04/2025

Explore an innovative, data-driven approach to hepatocellular carcinoma care.

A new article in Hepatology International introduces an explainable attention-enhanced heuristic paradigm for multi-view prognostic risk score development in HCC—paving the way for more accurate, transparent, and personalized clinical decision-making.

🔗 Read the full study here: https://link.springer.com/article/10.1007/s12072-025-10793-8

25/03/2025

📢 *New insights into Lean-MAFLD*

A comprehensive **systematic review and meta-analysis** in *Hepatology International* examines the **global prevalence, metabolic characteristics, and outcomes of Lean-MAFLD**, shedding light on this emerging phenotype of metabolic dysfunction-associated liver disease.

🔍 Explore the findings and their implications for clinical practice.

Read the full article here: https://link.springer.com/article/10.1007/s12072-025-10801-x